Rain Therapeutics (RAIN) is a clinical-stage precision oncology company. They recently went public in 2021. Co-founder and CEO, Avanish Vellanki, speaks about Rain Therapeutics’ internal growth potential as well as the effect that its new treatment Rain-32 will have. Vellanki states that Rain-32 has been seen to triple or quadruple the survival time of patients with difficult to treat cancer. Rain Therapeutics is continuing to build a pipeline of targeted cancer therapies. Tune in to find out more.
The Watch List
01 Jun 2021
SHARE
The Watch List
28 Apr 2022
The Watch List
20 Apr 2022
Morning Trade Live
18 Mar 2022
The Watch List
13 May 2022
The Watch List
01 Mar 2022
Trading 360
18 Apr 2022